ID   MTMRE_HUMAN             Reviewed;         650 AA.
AC   Q8NCE2; Q0JTH5; Q0JU83; Q6PIZ4; Q6QE21; Q86VK9; Q8IYK1; Q8TCM7;
AC   Q9H6C0;
DT   28-NOV-2006, integrated into UniProtKB/Swiss-Prot.
DT   28-NOV-2006, sequence version 2.
DT   10-MAY-2017, entry version 122.
DE   RecName: Full=Myotubularin-related protein 14;
DE            EC=3.1.3.-;
DE   AltName: Full=HCV NS5A-transactivated protein 4 splice variant A-binding protein 1;
DE            Short=NS5ATP4ABP1;
DE   AltName: Full=hJumpy;
GN   Name=MTMR14; Synonyms=C3orf29;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Chen L.D., Cheng J., Wang Q., Hong Y., Zhang L.F., Han L., Yuan J.;
RT   "Screening and cloning of interaction protein 1 of HCV NS5A-
RT   transactivated protein 4 splice variant A.";
RL   Submitted (MAY-2006) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Kidney epithelium, and Teratocarcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3).
RC   TISSUE=Duodenal adenocarcinoma, Leukocyte, Retinal pigment epithelium,
RC   and Rhabdomyosarcoma;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 403-557 (ISOFORM 1).
RC   TISSUE=Melanoma;
RA   Sales M.M., Ferrasi A.C., Pereira A.A., Pardini M.I.M.C.,
RA   Sogayar M.C., Camargo A.A.;
RL   Submitted (FEB-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   FUNCTION, INVOLVEMENT IN CNM1 AS MODIFIER OF PHENOTYPE, VARIANTS CNM1
RP   GLN-336 AND CYS-462, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND
RP   MUTAGENESIS OF CYS-330.
RX   PubMed=17008356; DOI=10.1093/hmg/ddl250;
RA   Tosch V., Rohde H.M., Tronchere H., Zanoteli E., Monroy N., Kretz C.,
RA   Dondaine N., Payrastre B., Mandel J.-L., Laporte J.;
RT   "A novel PtdIns3P and PtdIns(3,5)P2 phosphatase with an inactivating
RT   variant in centronuclear myopathy.";
RL   Hum. Mol. Genet. 15:3098-3106(2006).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-580, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [9]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-194, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-518; SER-530 AND
RP   SER-624, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-638, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.O113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V.,
RA   Aguiar M., Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C.,
RA   Vemulapalli V., Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
CC   -!- FUNCTION: Lipid phosphatase which efficiently dephosphorylates
CC       phosphatidylinositol 3-phosphate (PtdIns3P) and PtdIns(3,5)P2;
CC       inactive toward PtdIns4P, PtdIns(3,4)P2, PtdIns(4,5)P2 and
CC       PtdIns(3,4,5)P3. {ECO:0000269|PubMed:17008356}.
CC   -!- INTERACTION:
CC       Q05BL1:TP53BP2; NbExp=3; IntAct=EBI-5658424, EBI-11952721;
CC       Q13625-3:TP53BP2; NbExp=3; IntAct=EBI-5658424, EBI-10175039;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17008356}.
CC       Note=Found in reticular structures and plasma membrane ruffles.
CC       Concentrated near the nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q8NCE2-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8NCE2-2; Sequence=VSP_021586;
CC       Name=3;
CC         IsoId=Q8NCE2-3; Sequence=VSP_021585, VSP_021586;
CC   -!- TISSUE SPECIFICITY: Expressed in various tissues, including heart,
CC       skeletal muscle, placenta, liver, lung, kidney and pancreas.
CC       {ECO:0000269|PubMed:17008356}.
CC   -!- DISEASE: Myopathy, centronuclear, 1 (CNM1) [MIM:160150]: A
CC       congenital muscle disorder characterized by progressive muscular
CC       weakness and wasting involving mainly limb girdle, trunk, and neck
CC       muscles. It may also affect distal muscles. Weakness may be
CC       present during childhood or adolescence or may not become evident
CC       until the third decade of life. Ptosis is a frequent clinical
CC       feature. The most prominent histopathologic features include high
CC       frequency of centrally located nuclei in muscle fibers not
CC       secondary to regeneration, radial arrangement of sarcoplasmic
CC       strands around the central nuclei, and predominance and hypotrophy
CC       of type 1 fibers. {ECO:0000269|PubMed:17008356}. Note=The gene
CC       represented in this entry may act as a disease modifier. MTMR14
CC       mutations affecting enzymatic function have been found in sporadic
CC       cases of centronuclear myopathy, one of them carrying a disease-
CC       associated mutation in DNM2 (PubMed:17008356). This raises the
CC       possibility of MTMR14 being a modifier of the phenotype in some
CC       cases of centronuclear myopathy (PubMed:17008356).
CC       {ECO:0000269|PubMed:17008356}.
CC   -!- SIMILARITY: Belongs to the protein-tyrosine phosphatase family.
CC       Non-receptor class myotubularin subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB15340.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; DQ630520; ABG02221.1; -; mRNA.
DR   EMBL; AK026058; BAB15340.1; ALT_INIT; mRNA.
DR   EMBL; AK074792; BAC11211.1; -; mRNA.
DR   EMBL; AL713695; CAD28494.1; -; mRNA.
DR   EMBL; AM393309; CAL38187.1; -; mRNA.
DR   EMBL; AM393050; CAL37928.1; -; mRNA.
DR   EMBL; BC001674; AAH01674.2; -; mRNA.
DR   EMBL; BC025952; AAH25952.2; -; mRNA.
DR   EMBL; BC035690; AAH35690.1; -; mRNA.
DR   EMBL; BC050626; AAH50626.1; -; mRNA.
DR   EMBL; AY545552; AAS50151.1; -; mRNA.
DR   CCDS; CCDS43043.1; -. [Q8NCE2-1]
DR   CCDS; CCDS43044.1; -. [Q8NCE2-2]
DR   CCDS; CCDS43045.1; -. [Q8NCE2-3]
DR   RefSeq; NP_001070993.1; NM_001077525.2. [Q8NCE2-1]
DR   RefSeq; NP_001070994.1; NM_001077526.2. [Q8NCE2-2]
DR   RefSeq; NP_071930.2; NM_022485.4. [Q8NCE2-3]
DR   UniGene; Hs.475382; -.
DR   ProteinModelPortal; Q8NCE2; -.
DR   SMR; Q8NCE2; -.
DR   BioGrid; 122168; 8.
DR   IntAct; Q8NCE2; 8.
DR   MINT; MINT-3042111; -.
DR   STRING; 9606.ENSP00000296003; -.
DR   DEPOD; Q8NCE2; -.
DR   iPTMnet; Q8NCE2; -.
DR   PhosphoSitePlus; Q8NCE2; -.
DR   BioMuta; MTMR14; -.
DR   DMDM; 118568016; -.
DR   EPD; Q8NCE2; -.
DR   MaxQB; Q8NCE2; -.
DR   PaxDb; Q8NCE2; -.
DR   PeptideAtlas; Q8NCE2; -.
DR   PRIDE; Q8NCE2; -.
DR   DNASU; 64419; -.
DR   Ensembl; ENST00000296003; ENSP00000296003; ENSG00000163719. [Q8NCE2-1]
DR   Ensembl; ENST00000351233; ENSP00000334070; ENSG00000163719. [Q8NCE2-3]
DR   Ensembl; ENST00000353332; ENSP00000323462; ENSG00000163719. [Q8NCE2-2]
DR   GeneID; 64419; -.
DR   KEGG; hsa:64419; -.
DR   UCSC; uc003brz.4; human. [Q8NCE2-1]
DR   CTD; 64419; -.
DR   DisGeNET; 64419; -.
DR   GeneCards; MTMR14; -.
DR   HGNC; HGNC:26190; MTMR14.
DR   HPA; HPA054063; -.
DR   MalaCards; MTMR14; -.
DR   MIM; 160150; phenotype.
DR   MIM; 611089; gene.
DR   neXtProt; NX_Q8NCE2; -.
DR   OpenTargets; ENSG00000163719; -.
DR   Orphanet; 169189; Autosomal dominant centronuclear myopathy.
DR   PharmGKB; PA162396265; -.
DR   eggNOG; ENOG410IHSK; Eukaryota.
DR   eggNOG; ENOG410XSF4; LUCA.
DR   GeneTree; ENSGT00390000018852; -.
DR   HOVERGEN; HBG062969; -.
DR   InParanoid; Q8NCE2; -.
DR   KO; K18086; -.
DR   OMA; DTHLFDK; -.
DR   OrthoDB; EOG091G03F3; -.
DR   PhylomeDB; Q8NCE2; -.
DR   TreeFam; TF324044; -.
DR   BioCyc; MetaCyc:HS08920-MONOMER; -.
DR   BRENDA; 3.1.3.64; 2681.
DR   Reactome; R-HSA-1632852; Macroautophagy.
DR   Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane.
DR   ChiTaRS; MTMR14; human.
DR   GeneWiki; MTMR14; -.
DR   GenomeRNAi; 64419; -.
DR   PRO; PR:Q8NCE2; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000163719; -.
DR   ExpressionAtlas; Q8NCE2; baseline and differential.
DR   Genevisible; Q8NCE2; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0001726; C:ruffle; IDA:UniProtKB.
DR   GO; GO:0052629; F:phosphatidylinositol-3,5-bisphosphate 3-phosphatase activity; TAS:Reactome.
DR   GO; GO:0004438; F:phosphatidylinositol-3-phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0004722; F:protein serine/threonine phosphatase activity; TAS:Reactome.
DR   GO; GO:0004725; F:protein tyrosine phosphatase activity; IEA:InterPro.
DR   GO; GO:0016236; P:macroautophagy; TAS:Reactome.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome.
DR   Gene3D; 3.90.190.10; -; 1.
DR   InterPro; IPR029021; Prot-tyrosine_phosphatase-like.
DR   InterPro; IPR016130; Tyr_Pase_AS.
DR   SUPFAM; SSF52799; SSF52799; 2.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Complete proteome; Cytoplasm;
KW   Disease mutation; Glycoprotein; Hydrolase; Methylation;
KW   Phosphoprotein; Reference proteome.
FT   CHAIN         1    650       Myotubularin-related protein 14.
FT                                /FTId=PRO_0000260214.
FT   COMPBIAS    512    518       Poly-Ser.
FT   ACT_SITE    330    330       Phosphocysteine intermediate.
FT                                {ECO:0000250}.
FT   MOD_RES     194    194       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     518    518       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     530    530       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     580    580       Phosphoserine.
FT                                {ECO:0000244|PubMed:18220336}.
FT   MOD_RES     624    624       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     638    638       Omega-N-methylarginine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   CARBOHYD    226    226       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    519    519       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VAR_SEQ     479    538       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_021585.
FT   VAR_SEQ     539    590       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:17974005,
FT                                ECO:0000303|Ref.1}.
FT                                /FTId=VSP_021586.
FT   VARIANT     336    336       R -> Q (in CNM1; may act as a phenotype
FT                                modifier; drastically reduced enzymatic
FT                                activity; dbSNP:rs121434509).
FT                                {ECO:0000269|PubMed:17008356}.
FT                                /FTId=VAR_033370.
FT   VARIANT     462    462       Y -> C (in CNM1; may act as a disease
FT                                modifier; mutation found in a patient
FT                                also carrying mutation Lys-368 in DNM2;
FT                                reduced enzymatic activity;
FT                                dbSNP:rs121434510).
FT                                {ECO:0000269|PubMed:17008356}.
FT                                /FTId=VAR_033371.
FT   MUTAGEN     330    330       C->S: Drastically reduced enzymatic
FT                                activity. {ECO:0000269|PubMed:17008356}.
FT   CONFLICT     28     28       G -> R (in Ref. 3; CAL38187).
FT                                {ECO:0000305}.
FT   CONFLICT     55     55       E -> G (in Ref. 3; CAL37928).
FT                                {ECO:0000305}.
FT   CONFLICT    126    126       R -> G (in Ref. 3; CAL38187).
FT                                {ECO:0000305}.
FT   CONFLICT    390    390       F -> S (in Ref. 2; BAC11211).
FT                                {ECO:0000305}.
FT   CONFLICT    403    406       EEFS -> ALFA (in Ref. 5; AAS50151).
FT                                {ECO:0000305}.
FT   CONFLICT    554    557       GSWQ -> AAGM (in Ref. 5; AAS50151).
FT                                {ECO:0000305}.
FT   CONFLICT    646    646       S -> N (in Ref. 3; CAL37928).
FT                                {ECO:0000305}.
SQ   SEQUENCE   650 AA;  72203 MW;  C1B70E5140EF0716 CRC64;
     MAGARAAAAA ASAGSSASSG NQPPQELGLG ELLEEFSRTQ YRAKDGSGTG GSKVERIEKR
     CLELFGRDYC FSVIPNTNGD ICGHYPRHIV FLEYESSEKE KDTFESTVQV SKLQDLIHRS
     KMARCRGRFV CPVILFKGKH ICRSATLAGW GELYGRSGYN YFFSGGADDA WADVEDVTEE
     DCALRSGDTH LFDKVRGYDI KLLRYLSVKY ICDLMVENKK VKFGMNVTSS EKVDKAQRYA
     DFTLLSIPYP GCEFFKEYKD RDYMAEGLIF NWKQDYVDAP LSIPDFLTHS LNIDWSQYQC
     WDLVQQTQNY LKLLLSLVNS DDDSGLLVHC ISGWDRTPLF ISLLRLSLWA DGLIHTSLKP
     TEILYLTVAY DWFLFGHMLV DRLSKGEEIF FFCFNFLKHI TSEEFSALKT QRRKSLPARD
     GGFTLEDICM LRRKDRGSTT SLGSDFSLVM ESSPGATGSF TYEAVELVPA GAPTQAAWRK
     SHSSSPQSVL WNRPQPSEDR LPSQQGLAEA RSSSSSSSNH SDNFFRMGSS PLEVPKPRSV
     DHPLPGSSLS TDYGSWQMVT GCGSIQERAV LHTDSSLPFS FPDELPNSCL LAALSDRETR
     LQEVRSAFLA AYSSTVGLRA VAPSPSGAIG GLLEQFARGV GLRSISSNAL
//
